<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669172</url>
  </required_header>
  <id_info>
    <org_study_id>EC-HEM-HGUGM-2016-01</org_study_id>
    <nct_id>NCT03669172</nct_id>
  </id_info>
  <brief_title>Efectiveness of Donor IL-15-stimulated NK Cells Post Transplant Infusion in in Acute Leukemia</brief_title>
  <official_title>Fase I/II, Unicentric, Historical Control Clinical Trial to Evaluate the Effectiveness of Donor IL-15 Stimulated NK Cells Post Transplant Infusion, in Acute Leukemia Patients With Poor Prognosis and Haploidentical Unmanipulated Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martín, José Luis Díez, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martín, José Luis Díez, M.D.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial phase I and II, single-center, historical control, to evaluate the&#xD;
      effectiveness of donor IL-15 stimulated NK cells post transplant infusion, in acute leukemia&#xD;
      patients with poor prognosis and haploidentical unmanipulated transplant&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial wants to study the safety, effectiveness and efficacy of NK cells&#xD;
      incubated infusion (CD56 +, CD3) incubated ex vivo with IL-15 infusion in patients with high&#xD;
      risk acute myeloid leukemia undergoing allogeneic transplant of an haploidentical donor with&#xD;
      post-transplant cyclophosphamide administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Actual">July 6, 2021</completion_date>
  <primary_completion_date type="Actual">July 6, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>Up to 2 years after first infusion</time_frame>
    <description>Number of Treatment-Related Adverse Events as Assessed by CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reevaluation of the Minimal residual disease (MRD)</measure>
    <time_frame>Up to 1 year after first infusion</time_frame>
    <description>Reevaluation of the Minimal residual disease (MRD) in bone marrow by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>ACUTE LEUKEMIA</condition>
  <arm_group>
    <arm_group_label>NK cells infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NK cells incubated infusion (CD56 +, CD3) ex vivo with IL-15 in patients with acute myeloid leukemia undergoing high-risk allogeneic haploidentical Pt-C donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor IL-15 stimulated NK cells infusion</intervention_name>
    <description>DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSIS AND HAPLOIDENTICAL UNMANIPULATED TRANSPLANT</description>
    <arm_group_label>NK cells infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. More than 18 years old, with acute myeloid leukemia who goes to undergo haploidentical&#xD;
&#xD;
          2. Assessable disease by analytic, molecular or image techniques.&#xD;
&#xD;
          3. Comorbidity Sorror index less than 6.&#xD;
&#xD;
          4. Give informed consent according to the legal requirements.&#xD;
&#xD;
          5. Dispose of a donor without exclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive HIV serology.&#xD;
&#xD;
          2. Patients with an active infection or other underlying serious medical statement.&#xD;
&#xD;
          3. Any medical process, analytical abnormality or important psychiatric disorder,&#xD;
             according to the investigator's opinion, that prevent the participation of the patient&#xD;
             in the study.&#xD;
&#xD;
          4. Participation of any other interventional clincal trial within 30 days of planned&#xD;
             enrollment into this study.&#xD;
&#xD;
          5. Women who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

